Tuesday marked a prominent medical development as Russia administered the first dose of a personalized cancer vaccine to a patient, representing a milestone in the country’s efforts to develop targeted and effective immunotherapies against malignant tumors. This announcement serves as a new ray of hope for millions of people facing complex health challenges due to cancerous diseases, as the transition from traditional chemotherapy and radiotherapy to personalized biological and immunotherapies represents a massive leap in modern medicine.
This innovative vaccine has been named «NeoOncoVax» and was given to a 60-year-old resident of the Kursk region who was diagnosed with malignant skin cancer known as melanoma, according to an official statement issued by the Russian Ministry of Health and reported by accredited news agencies.
This delicate medical procedure was carried out at the National Medical Research Center for Radiology in the capital, Moscow, where the patient received the experimental mRNA-based vaccine alongside the ongoing immunotherapy he is undergoing, forming a dual and intensive treatment approach.
Mechanism of action of the innovative vaccine
The design of the «NeoOncoVax» vaccine relies fundamentally on mRNA technology, the same pioneering technology that was widely and successfully used in the production of certain vaccines against COVID-19. However, the core and unique difference here lies in the fact that this vaccine is fully designed and customized to match each individual patient’s tumor. The concept of personalization in medicine is reaching its peak with this innovation.
According to the National Medical Research Center for Radiology, the vaccine is developed based on the genetic profiling of the patient’s tumor, where a sample of the tumor tissue is taken and genetic material is extracted to identify unique genetic mutations. Based on this complex map, the vaccine is designed to «teach» and train the immune system to detect and destroy cancer cells with extreme precision, while minimizing potential damage to surrounding healthy tissues.
«For the first time, we have used an mRNA-based vaccine specifically designed for an individual patient. This represents a completely different approach, not just to treating the disease, but to training the immune system to recognize those cells that pose a threat and destroy them definitively.»
Treatment protocol and timeline challenges
The new treatment protocol requires a long-term commitment from both the patient and the attending medical team, as the treatment schedule involves administering up to 10 consecutive doses of the vaccine, paired with a course of immunotherapy. Time is a critical factor in this process; manufacturing this personalized vaccine in specialized laboratories takes between 3 to 4 months from the date of taking the patient’s tissue biopsy.
Currently, the use of this vaccine is limited to adult patients suffering from unresectable skin cancer or that has already spread to other parts of the body.
A long road toward comprehensive approval
The Russian Ministry of Health had approved the clinical use of the «NeoOncoVax» vaccine in November 2025, and the Gamaleya National Research Center of Epidemiology and Microbiology produced the initial test batches by late that year. In this regard, Alexander Gintsburg, head of the Gamaleya Center, claimed that the vaccine’s efficacy could exceed the 90% threshold based on preclinical studies conducted on animals.
On a parallel track, Russia is separately working on developing another vaccine named «Entromix», which is peptide-based and targets colorectal tumors. The Russian government plans to include both vaccines in the mandatory medical insurance program by 2026, aiming to provide these advanced treatments free of charge to patients.
The global race to develop immunotherapies
This Russian announcement comes amid broader international efforts striving to develop personalized anti-tumor vaccines. The annual meeting of the American Association for Cancer Research, scheduled for April 17–22 in San Diego, is set to feature presentations from leading companies such as a unit of «CK Life Sciences», which plans to present important data.
Key highlights of global competition include:
- BioNTech’s collaboration with the UK’s National Health Service to deliver personalized vaccines to up to 10,000 patients by 2030.
- Moderna’s announcement of highly encouraging results from its cancer immunotherapy trials.
Despite these high hopes, independent experts have urged caution, noting an urgent need for large-scale, peer-reviewed clinical trials before the efficacy of these modern technologies can be definitively and finally evaluated.
Frequently Asked Questions
What is the «NeoOncoVax» cancer vaccine?
It is a personalized Russian vaccine based on mRNA technology, custom-designed for each patient based on the genetic map of their tumor, aimed at training the immune system to recognize and attack cancer cells with precision.
How long does the production of a patient’s personalized vaccine take?
The manufacturing process of the vaccine in specialized medical laboratories takes between 3 to 4 months after taking a biopsy of the patient’s tumor to extract the necessary genetic data.
Will this treatment be available for free?
Yes, the Russian government plans to include this vaccine, alongside other vaccines such as «Entromix», in the mandatory medical insurance program by 2026 to be provided free of charge to Russian patients.
